Investors & Media
At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.
Press Releases
Subscribe to receive breaking news alerts about uniQure.
Subscribe-
-
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
-
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
Stock Information
Updated stock ticker information for uniQure
- NASDAQ:
- Price:
- Change:
- Volume:
(Updated every 15 minutes)
SEC Filings
Security and exchange commission filings for uniQure, including quarterly and annual reports
Learn MoreUpcoming Webcasts
No webcasts scheduled. Check back soon.
Webcast Archive
-
Phase I/II AMT-130 Huntington's Disease Update
8:30 a.m. - 9:30 a.m.
View Webcast -
uniQure Second Quarter 2026 Earnings Call
8:30 a.m. - 9:30 a.m. ET
View Webcast -
2026 RBC Capital Markets Global Healthcare Conference
11:30 a.m. ET - 12:00 p.m. ET
View Webcast
Investor Presentations
-
Phase I/II AMT-130 Additional Data Update – Phase I/II AMT-130 Update 36 Month Data and 48 Month Analysis - September 2026
View Presentation -
Pivotal Phase I/II AMT-130 Program Update – Phase I/II AMT-130 Pivotal 36 Month Analysis - September 2025
View Presentation -
CHDI - 2026 HD Therapeutics Conference – AMT-130: Propensity Score Adjustment Mitigates Potential Bias from Striatal Volume Absence in Enroll-HD
View Presentation -
9th Epilepsy Pipeline Conference – GenTLE Phase I/IIa Clinical Study of AMT-260: Preliminary Results of an Investigational Gene Therapy for Refractory MTLE
View Presentation -
2026 WORLDSympsium – AMT-191 investigational gene therapy in adult males with classic Fabry disease; preliminary safety and biomarker data of Phase I/IIa study
View Presentation